A major limitation lies in the context dependence of its signalling pathways; Piezo1’s functional output in CAFs can vary fundamentally depending on tumour type and microenvironmental composition, raising questions about its suitability as a universal therapeutic target. The gene discussed is PIEZO1; the disease is neoplasm.